What’s the Big Deal About Gene Therapy?
The past few months have been revolutionary in
Gene Therapy and CRISPR Technology
Genes are the instructions of life, so to speak, providing the template for necessary proteins to form and go about their daily business: that is, keeping you alive. Variations within the genome (your complete set of genes) are the reason why all of us are different, both from the inside and on the outside. Sometimes, however, these variations can cause your body to react negatively – leading to genetic diseases.
The concept of altering the genome has been around since 1972, with the aim to modify or replace faulty genes with healthy ones. Hence treatment of genetic diseases was possible by targeting the source – the very DNA that codes for life. Once thought of as the perfect treatment – combining efficacy and specificity with safety and mild side effects – the hype for gene therapy died off due to clinical failures.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology hails from bacterial defense systems. Used to destroy the DNA of invading viruses, ‘CRISPR’ can target cut strands of DNA at very precise locations1. Once cut, the cell’s own DNA repair machinery can add or delete base pairs, or replace an existing segment with a brand new gene.
In 2012, Jennifer Doudna and colleagues published a new and improved CRISPR ‘cutting technique’ that would allow it to perform faster, cheaper and with greater ease of design and higher efficiency2. Because of this, a whole world of opportunities was reopened. Before long, pharmaceutical companies started to discover hit compounds – or genes in this case – formed from CRISPR. These promising compounds quickly progressed to pre-clinical and clinical trials with the support of regulatory agencies like the FDA.
Leber’s congenital amaurosis (LCA) is an inherited disorder causing progressive blindness, associated with a mutation in the RPE65 gene. Enter
13-year-old patient Jack Hogan was the first recipient of post-approval Luxturna, in March 2018; his surgery was performed by
Future of Gene Therapy
Luxturna proved that it was possible to reverse a disease at its source, the little fault in the genome, so to speak. Furthermore, Luxturna gave hope to patients of inherited diseases that a cure was possible, that genes do not necessarily define you. All around the world, an increasing number of pharmaceutical companies are investing in gene therapy research.
Inevitably, this number will increase in the future. There are immense possibilities for the development of therapies to treat inherited diseases. It won’t be long before the focus moves to alter other aspects of the genome such as physical appearance, muscle growth, even intellect. Captain America’s Super-Soldier Serum and the elixir of youth might not be too far down the list.
Update: In November 2018, Chinese scientist He Jiankui announced the world’s first successful human DNA editing experiment. The embryos of a pair of twins were altered, removing a gene that reduces the susceptibility of the babies to HIV. Because of the ethical issues involved, this sparked a global outcry about CRISPR technology and gene therapy. Read the full story on CNN.
- Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. Nature protocols, 8(11), 2281.
- Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. science, 1225829.